MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis

Objective To compare the American College of Rheumatology paediatric (ACRp) response criteria and conventional radiography with MRI findings in a cohort of patients with juvenile idiopathic arthritis. Methods Forty consecutive patients (30 girls, 10 boys; median age 10.8 years) with arthritis of the wrist starting treatment with disease-modifying antirheumatic drugs or biological agents were recruited. At 1-year follow-up the treatment response was assessed by ACRp criteria and radiographic progression using the adapted Sharp/van der Heijde method. Wrist MRIs were evaluated using both the paediatric-MRI and the OMERACT rheumatoid arthritis MRI scores. Sensitivity to change of clinical and imaging variables was assessed by standardised response mean (SRM) and relative efficiency (RE) was used to compare SRMs. Results ACRp90 responders showed a significantly higher decrease in MRI synovitis score (median change −4) than non-responders (median change 0), ACRp30–50 responders (median change 0) and ACRp70 responders (median change −1) (p=0.0006, Kruskal–Wallis test). Non-responders showed significantly higher radiographic progression than ACRp90 responders (pB=0.016). The MRI synovitis score showed a greater responsiveness to change (SRM 1.69) compared with the majority of ACR core set of variables. MRI erosion scores were less responsive than conventional radiography in detecting destructive changes (RE <1). MRI follow-up revealed no signs of inflammation in four out of 24 wrists with clinically inactive disease. Conclusion Only ACRp90 responders showed a significant decrease in synovitis and the halting of structural damage, suggesting that levels of response higher than ACRp30 are more appropriate for assessing drug efficacy. The excellent responsiveness of MRI and its ability to detect subclinical synovitis make it a promising outcome measure.

[1]  C. Swanton,et al.  Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Lane,et al.  Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance , 2015, Pediatric Rheumatology.

[3]  J. Roth,et al.  Ultrasound findings on patients with juvenile idiopathic arthritis in clinical remission , 2011, Arthritis care & research.

[4]  M. Beresford,et al.  Juvenile Idiopathic Arthritis , 2011, Paediatric drugs.

[5]  K. Rosendahl,et al.  The paediatric wrist revisited: redefining MR findings in healthy children , 2010, Annals of the rheumatic diseases.

[6]  M. Valle,et al.  Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis , 2010, Annals of the rheumatic diseases.

[7]  A. Martini,et al.  Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. , 2010, Arthritis and rheumatism.

[8]  Alberto Martini,et al.  Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis , 2010, Pediatric Radiology.

[9]  C. Wouters,et al.  Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension , 2009, Annals of the rheumatic diseases.

[10]  Curzio Basso,et al.  Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. , 2010, Rheumatology.

[11]  P. Woo.  Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders , 2009, Current opinion in rheumatology.

[12]  C. Wallace,et al.  Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis , 2009, Arthritis research & therapy.

[13]  A. Boonen,et al.  Monitoring anti-TNFα treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage , 2008, Annals of the rheumatic diseases.

[14]  S. Berney.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2009 .

[15]  M. Valle,et al.  Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[16]  K. Minden,et al.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. , 2008, The New England journal of medicine.

[17]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[18]  A. Martini,et al.  Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. , 2008, Clinical and experimental rheumatology.

[19]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[20]  P. Tugwell,et al.  Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[21]  A. Martini,et al.  The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis , 2007, Annals of the rheumatic diseases.

[22]  A. Martini,et al.  Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[23]  C. Wouters,et al.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[24]  C. Peterfy,et al.  Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. , 2006, Arthritis and rheumatism.

[25]  B. Dardzinski,et al.  Quantitative magnetic resonance imaging of the hands and wrists of children with juvenile rheumatoid arthritis. , 2005, The Journal of rheumatology.

[26]  H. Thomsen,et al.  Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment , 2005, Annals of the rheumatic diseases.

[27]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[28]  E. Giannini,et al.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.

[29]  R. Saurenmann,et al.  A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. , 2004, Arthritis and rheumatism.

[30]  E. Rostrup,et al.  Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[31]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[32]  Maarten Boers,et al.  Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.

[33]  A. Martini,et al.  Early predictors of outcome in juvenile idiopathic arthritis. , 2003, Clinical and experimental rheumatology.

[34]  Paul Bird,et al.  OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. , 2003, The Journal of rheumatology.

[35]  Paul Bird,et al.  Computerized measurement of magnetic resonance imaging erosion volumes in patients with rheumatoid arthritis: a comparison with existing magnetic resonance imaging scoring systems and standard clinical outcome measures. , 2003, Arthritis and rheumatism.

[36]  M. Argyropoulou,et al.  The role of MRI in the evaluation of hip joint disease in clinical subtypes of juvenile idiopathic arthritis. , 2002, The British journal of radiology.

[37]  S. Cavuto,et al.  The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). , 2001, Clinical and experimental rheumatology.

[38]  Andre Peeters,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis , 2000 .

[39]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[40]  D. Felson,et al.  Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.

[41]  Avril Drummond,et al.  Analysis and presentation of data , 1996 .

[42]  M H Liang,et al.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. , 1985, Arthritis and rheumatism.

[43]  Giannini Eh,et al.  Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. , 1982 .

[44]  Giannini Eh,et al.  Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. , 1982 .

[45]  E. Giannini,et al.  Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. , 1982, The Journal of rheumatology.

[46]  Methodology and studies of children with juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group (PRCSG). , 1982, The Journal of rheumatology.